When Design Therapeutics DSGN+0.82%, Inc. (DSGN) reported four-week results for DT-216P2 in May, biotech 865238-0.87% ...
In the crowded history of early twentieth-century neurology, the names that survive in eponyms are usually those of men. Yet one of the most elegant clinical descriptions of a hereditary neurological ...
Charlotte Casey, aged 25, and her 28 year-old sister Olivia Dews suffer from a rare genetic condition called Friedreich’s ...
Higher levels of high-sensitivity cardiac troponin T were independently associated with lower myocardial capillary density in ...
Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief ...
Hartlepool Mail on MSN
Hartlepool Friedreich's ataxia patient cheers campaign to secure Parliament debate on wonder drug omaveloxolone
A Hartlepool woman campaigning for access to a life-enhancing drug says she is proud after a petition secured 100,000 signatures to secure a debate in parliament.
Irish Examiner on MSN
Friedreich’s ataxia patients could yet wait years to receive life-changing drug, group warns
Friedreich’s ataxia patients met with staff from Tallaght Hospital last week who explained the limitations in the current ...
Important research news last week included US biotech Celldex Therapeutics releasing positive Phase III results for ...
By Scott DiSavino and Lewis Krauskopf NEW YORK, Sept 26 (Reuters) - A strong nor'easter hitting the US East Coast from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results